Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Lucia Masarova, Meixian Huang, Sharon Bledsoe, Naveen Pemmaraju, Tapan M. Kadia, Prithviraj Bose, Jo Ishizawa, Guillermo Montalban-Bravo, Mi-Ae Lyu, Ke Zeng, Tara Sadeghi, Ekatherine Asatiani, Simrit Parmar, Christopher R. Flowers, Hagop M. Kantarjian

Blood (2023) 142 (Supplement 1): 1813.

https://doi.org/10.1182/blood-2023-188051

Published: 2023

Journal Articles

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

Stephen T. Oh, MD, Jason Gotlib, MD MS, Sanjay Mohan, MD MSCI, Haris Ali, MD, Ekatherine Asatiani, MD, Francis Seguy, Feng Zhou, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-134574

Published: 2020

Journal Articles

Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias

Eric J. Feldman, MD, Jeffrey Lancet, MD, Jonathan E. Kolitz, MD, Ellen Ritchie, MD, Alan F. List, MD, Ekatherine Asatiani, MD, Tania J Curcio, Michelle Burton, RN, Marge Fricano, BSN, Christine Swenson, Lawrence D Mayer, PhD, Arthur C. Louie, MD

Blood (2008) 112 (11): 2984.

https://doi.org/10.1182/blood.V112.11.2984.2984

Published: 2008

Journal Articles

Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph + + Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

Jorge Cortes, MD, Ronald Paquette, MD, Moshe Talpaz, Javier Pinilla, MD, PhD, Ekatherine Asatiani, MD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, Corynn Kasap, BS, Lynne A. Bui, MD, Douglas O. Clary, PhD, Neil Shah, MD, PhD

Blood (2008) 112 (11): 3232.

https://doi.org/10.1182/blood.V112.11.3232.3232

Published: 2008

Journal Articles

Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS).

Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz, Ekatherine Asatiani, Tania J. Curcio, Michelle K. Burton, Marjorie Fricano, Amanda R. Begley, Christine Swenson, Lawrence Mayer, Andrew S. Janoff, Arthur C. Louie

Blood (2007) 110 (11): 900.

https://doi.org/10.1182/blood.V110.11.900.900

Published: 2007

Journal Articles

Flow Cytometric Analysis in Myelodysplastic Syndrome (MDS).

Jody L. Jordan, MD, Ekatherine Asatiani, MD, Dan P. Hartmann, MD, Bruce D. Cheson, MD, Metin Ozdemirli, MD

Blood (2005) 106 (11): 4932.

https://doi.org/10.1182/blood.V106.11.4932.4932

Published: 2005

NARROW

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias

Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph + + Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS).

Flow Cytometric Analysis in Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias

Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph + + Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS).

Flow Cytometric Analysis in Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only